|Articles|February 1, 1997

Looking Beyond the Formulary Budget: Cost Analysis and a Psychiatric Perspective
Volume 3
Issue 2 Suppl

Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Author(s)Gary L. Viale, PharmD

Download PDF: Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Articles in this issue

over 29 years ago

Article

Introduction: Looking Beyond the Formulary Budget

over 29 years ago

Article

Looking Beyond the Formulary Budget in Cost-Benefit Analysis

over 29 years ago

Article

Retrospective Analysis of the Effect of Risperidone on Clinical Outcome

over 29 years ago

Article

Newer Antipsychotic Medications: Discussions

over 29 years ago

Article

Bibliography

over 29 years ago

Article

Participants

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Evaluating the Cost Effectiveness of Newer Psychotropic Medications

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies

FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology

5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol